News Article | May 12, 2017
— Global Laboratory Chemicals Market by products (Molecular biology, Cytokine and chemokine testing, Carbohydrate analysis, Immunochemistry, Cell/tissue culture, Environment testing, and Biochemistry), by end-user applications (Biotechnology, Academic segments, Nonacademic segment, corporate segment): Forecast to 2027 Basically, laboratory chemicals are the compounds or substances that are used in chemical reaction to measure produce and detect other chemical substance. These are being used in the large scale for commercial applications and research purpose. The laboratory chemicals market will rise mainly due to significant increase in use of laboratory chemical in basic research combined with commercial applications. Moreover, growing interest of world scientific community in laboratory chemical is anticipated to escalate the growth in the market. Study Objectives of Laboratory Chemicals Market: • To provide detailed analysis of the market structure along with forecast for the next 10 years of segments and sub • segments of the global laboratory chemicals Market. • To provide insights about factors affecting the market growth. • To analyze the global laboratory chemicals Market based on various factors- price analysis, supply chain analysis, Porter’s five force analysis etc. • To provide historical and forecast revenues of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW). • To provide country level analysis of the market with respect to the current market size and future prospects • To provide country level analysis of the market for segment by product types, and end-users. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global laboratory chemicals market. The global laboratory chemicals market is segmented into product types, and end-user applications. On the basis of product types the market is segmented into Molecular biology, Cytokine and chemokine testing, Carbohydrate analysis, Immunochemistry, Cell/tissue culture, Environment testing, and Biochemistry. On the basis of end-user applications it is segmented as Biotechnology, Academic segments, Nonacademic segment, corporate segment. The key players present in the global laboratory chemical market mainly includes • Lonza Biologics ltd. • PerkinElmer Inc. • BD Biosciences • bioMerieux • Beckman Coulter Inc. • CALTAG Laboratories • GE healthcare • EMD Chemicals Inc. • Life technologies Corporation • Meridian Life science Inc. • Shimadzu Biotech • Takara Bio Inc. The report covers Geographies such as: Request for Table of Content at https://www.marketresearchfuture.com/request-toc/923 The market research report for Laboratory Chemicals of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report provides deep insights into current market scenario, historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. For more information, please visit https://www.marketresearchfuture.com/reports/laboratory-chemicals-market
News Article | May 16, 2017
The report, authored by the economic and public policy firm TClower & Associates, shows that California is home to over 12,000 life science establishments, including academic institutions and both small and large businesses. Organizations in California received nearly $3.6 billion in funding from the National Institutes of Health during 2016, the largest value in grants of all 50 states. According to the report, Los Angeles County is home to more than 2,400 individual establishments in the life science industry, including 103 biopharmaceutical companies, 436 medical device and diagnostic companies and 787 research and lab support institutions. The industry employs nearly 70,000 people, generates $40.3 billion in county economic output and increases labor income by $11.9 billion. Its local establishments were awarded over $890 million in NIH research awards in the 2016 fiscal year. "The Los Angeles life science industry is in a growth phase, with particular strength in biopharmaceuticals and life science wholesale trade," said Dina Lozofsky, executive director of Biocom's Los Angeles office. "We are under-recognized as a cluster, perhaps because our 2,400 industry establishments are spread out throughout the county instead of having a natural hub, but Los Angeles county brings in more NIH dollars to California than any other county in the state, and we have distinct strength in manufacturing in life sciences, hearkening to Los Angeles' historical strength in manufacturing." With 1,200 unique life science establishments, San Diego County's life science industry provides nearly 50,000 jobs and supports 133,000 jobs in the county, for a total countywide impact of more than 183,000 jobs. It generates $33.6 billion in economic output and adds $19.4 billion to the local gross product. Life science establishments brought over $832 million in NIH grants to San Diego during the 2016 fiscal year. Importantly to the region, San Diego boasts a location quotient of 1.98. Location quotients, determined by the Bureau of Labor Statistics, compare regional industry employment levels to the U.S. overall; and a figure greater than 1.2 indicates a competitive advantage. San Diego's level exceeds that, and has increased from 1.81 in 2011. Long recognized as a life science powerhouse, the nine counties that comprise Northern California's life science industry generate almost $114 billion in economic output, employ 96,000 people and support more than 302,000 jobs. It all adds up to a region-wide impact of nearly 400,000 jobs and contributes $68.6 billion per year to the state gross product. Northern California's 2,472 life science institutions are spread out among many counties with 500 establishments in Alameda County, 291 in San Francisco County, 367 in San Mateo County and 704 in Santa Clara County. "The life science industry, with its often near-philanthropic commitment to improving human health and the environment, is distinctly important to our economy and quality of life in California," Panetta said. "It's our vision at Biocom to empower all people in California — and across the county, frankly — to understand the important role of the life sciences in our state and to help the industry continue to prosper. As a unifying force for our state, Biocom is uniquely qualified to provide the tools to help each of California's life science hubs expand, leveraging their individual strengths and areas of focus." Click here for California Fact Sheet Click links below for fact sheets on specific life science communities: - Northern California - Southern California - Los Angeles County - Orange County - San Diego County - City of San Diego Biocom is the largest, most experienced leader and advocate for California's life science sector. We work on behalf of more than 900 member companies to drive public policy, build an enviable network of industry leaders, create access to capital, introduce and grow cutting-edge STEM education programs, and create robust value-driven group purchasing programs. Founded in 1995 in San Diego, Biocom provides the strongest public voice to research institutions and companies that fuel the local and state-wide economy. Our goal is simple: to help our members produce novel solutions that improve the human condition. In addition to its San Diego headquarters, Biocom operates a core office serving the Los Angeles market, satellite offices in Washington, D.C. and Tokyo, and has a continuous staff presence in the San Francisco Bay Area and in Sacramento. Our broad membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as to research universities and institutes, clinical research organizations, investors and service providers. For more information on Biocom, please visit our website at www.biocom.org. Connect with us on LinkedIn, Facebook, and Twitter (@BIOCOMCA). To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/californias-life-science-industry-generates-almost-317-billion-annually-supports-more-than-11-million-jobs-300458169.html
News Article | May 17, 2017
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 17, 2017) - Life science firms allowing regional teams to design their own medical education strategies increase the risk of misaligned company strategies, according to a recently published study by business intelligence firm, Cutting Edge Information. The data in Medical Education: Innovating CME to Improve Patient Outcomes revealed that the majority (57%) of surveyed Top 10 company teams operate a decentralized approach. In a decentralized approach, medical education strategies are developed at the global and/or corporate level and regional teams have responsibility of implementing the strategies. Compared to other company types, only 33% of Top 50 company teams are decentralized, while zero percent of small company teams favor the decentralized approach. The overall message from a pharmaceutical company can be muddled if its medical education strategy is misaligned with other external-facing groups' strategies, such as medical publications and medical science liaisons (MSLs). On the other hand, allowing regional teams to set their own strategies ensures that medical education tactics fit well with local policies. For this reason, one surveyed Top 50 company executive reports putting external medical affairs groups into one team, ultimately promoting cohesion and strategic alignment. "No two medical education teams are identical," said Natalie DeMasi, research team leader at Cutting Edge Information. "As far as decision making goes, most teams surveyed have global teams set medical education strategy, but regional teams are allowed to modify these strategies to meet local needs." Alternatively, many Top 50 (43%) and most small company teams (83%) surveyed have partially centralized structures, according to the study. In this setup, the global/corporate team develops medical education strategy and hands it down to the regional teams. Regional teams then tweak these strategies to meet local needs and regulations. All (100%) surveyed Top 10 and Top 50 medical education teams allow regional teams to modify global strategies. Medical Education: Innovating CME to Improve Patient Outcomes, available at https://www.cuttingedgeinfo.com/product/medical-education/, includes detailed metrics, best practices and insights into four main areas of medical education: This report examines medical education investments and staffing resources, as well as activities, trends, and event planning approaches. It highlights new, exciting ways that teams are elevating the value of medical education. For more information about Cutting Edge Information's medical affairs and medical education industry research, visit https://www.cuttingedgeinfo.com/product-category/medical-affairs/.
News Article | May 23, 2017
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 23, 2017) - Market access teams across Top 10, Top 50 and small pharmaceutical companies are more likely to employ higher numbers of full-time equivalents (FTEs) to support government accounts compared to pharmacy accounts, according to a recently released study by business intelligence provider, Cutting Edge Information. Recent research published in Global Market Access Strategies: Building Payer Relationships Through Comprehensive Value Stories found that among surveyed companies with government account managers, the number of total staff ranges from 0.5 to 19 FTEs. By comparison, the study found that the few surveyed teams with pharmacy account managers employ between 1 and 2 FTEs. "Life science firms may require higher numbers of government account managers to address payers' market access needs thoroughly – both at national and regional levels," said Eric Bolesh, senior director of product development at Cutting Edge Information. "Typically, government account managers are employed to navigate complex administrative systems at the local level." Employing a higher number of government account managers is ideal for Top 10 and Top 50 pharmaceutical firms because they are more likely to interact with payers in countries that have fragmented market access structures. With the exception of one Top 10 company's group, which employs 19 government account managers, the study found that remaining surveyed teams at Top 10 and Top 50 organizations employ anywhere between 0.5 and 5 FTEs. Smaller medical and device company teams with government account managers in place each report employing a single FTE. Global Market Access Strategies: Building Payer Relationships Through Comprehensive Value Stories, available at https://www.cuttingedgeinfo.com/product/global-market-access-strategies/, explores emerging trends impacting market access teams and the best practices they implement to obtain better pricing and reimbursement around the world. The study contains detailed market access performance metrics, including ideal time frames for involving market access teams in supporting new product launches. Use the report's benchmarks and market access team priorities to: For more information about Cutting Edge Information's market access research, please visit https://www.cuttingedgeinfo.com/product-category/market-access/.
News Article | April 27, 2017
RESEARCH TRIANGLE PARK, NC--(Marketwired - April 27, 2017) - The majority (82%) of surveyed drug manufacturers reported conducting -- or planning to conduct -- observational studies last year, which has become more common, according to a study by business intelligence research company Cutting Edge Information. The data published in Post-marketing Study Excellence: Design Phase 4 Trials to Demonstrate Real-World Outcomes show that from 2014 to 2016, the frequency of surveyed firms conducting observational studies remained relative flat -- only a slight decrease from 84% to 82%. Compared to interventional trials, Phase 4 observational studies require less human and spending resources. Observational studies are those in which investigators are not required to influence or impact study participants. Instead, investigators look for the natural relationships between factors impacting the study population and specific outcomes. Observational trials allow pharmaceutical companies to gather valuable, descriptive real-world data. Companies use these post-marketing studies to gather information related to product usage patterns, cost-effectiveness and long-term effectiveness. "Because these trials don't have the complex elements related to traditional clinical trials or interventional studies, post-marketing teams can focus less time on investigator training," said Natalie DeMasi, research team leader at Cutting Edge Information. "Life science firms find observational studies particularly accessible compared to more involved experimental studies because the training timeline is shorter." Observational studies can look to both prospective and retrospective data to inform findings. Even prospective studies, which follow patients through a predetermined period of time, can call on retrospective data. In fact, the majority (60%) of surveyed life science companies used or included retrospective data in their Phase 4 observational studies. Despite their advantages, observational trials have drawbacks. Real-world data collected in observational studies have higher external validity but will probably not yield data with the internal validity that interventional studies have. Additionally, observational studies can be more complicated in terms of protocols and statistical analyses. Life science teams must weigh all these different considerations carefully when planning their post-marketing studies. Post-marketing Study Excellence: Design Phase 4 Trials to Demonstrate Real-World Outcomes, available at https://cuttingedgeinfo.com/product/phase-4-clinical-trials/, provides strategic insights and key performance metrics on post-marketing research ownership, spending and staffing levels, as well as trend analysis. Data are broken down for interventional and observational studies and the report outlines the effectiveness of study outcomes due to early planning. Report highlights include: To learn more about Cutting Edge Information and post-marketing study management, please download the brochure at: https://cuttingedgeinfo.com/preview/phase-four-clinical-trials/.
News Article | February 15, 2017
Life science companies can now confidently meet industry regulatory and quality demands with assistance from powerful new compliance consultancy ARCexperts SALT LAKE CITY, UT--(Marketwired - Feb 14, 2017) - Achieving and maintaining FDA approval can be a tough challenge for life science companies. Especially for small to mid-size organizations that can't always support the internal personnel required to manage the vast array of compliance and quality demands placed on regulated companies. With the launch of ARCexperts, these companies have an opportunity to receive world-class audit, risk, and compliance consulting from a team of compliance experts that each brings more than 15 years of experience and most are recognized industry key opinion leaders (KOLs). Their services are designed to streamline the quality and compliance process for small to mid-size pharmaceutical, medical device, biotech and related life science industry companies. From securing proper product submissions, to launch and commercialization support, to audits, to assistance in building a healthy and validated quality management system (QMS) -- ARCexperts offers powerful and trusted advisors and services. "The regulatory and quality system requirements that all life science organizations face increases every year and the requirements themselves continue to evolve and change," said ARCexperts CEO and Founding Partner Walt Murray. "ARCexperts helps these companies in assessing their current state, providing roadmap recommendations to secure approved product and technology submissions, regulatory body compliance and the team support to help maintain a validated QMS. These are the 'must-haves' of operating as a regulated company. With our assistance, these companies can operate confidently knowing these requirements and processes are manageable and maintained." "Our global customers depend on us to ensure that they can go to market efficiently with their products or services, knowing that they are not going to be surprised by receiving notices from any regulatory body that their operation and goods are not compliant," said ARCexperts COO and Managing Partner Leslie Norris. "ARCexperts helps regulated organizations by sharing the process of performing the audits, QMS development, standards and submission requirements, along with staff training in order to maintain a risk mitigated environment." About ARCexperts ARCexperts is an industry leading regulatory compliance and quality systems consulting firm that provides in-depth services to small and mid-size organizations in the pharmaceutical, medical device, biotech and related life science industries. Their consultants are globally recognized KOLs that frequently speak and present at global conferences. Their services are offered on either a by-project basis or as an on-going service providing Quality and Compliance as a Service (QCaS). For additional information on ARCexperts, call 1.801.878.9945, email email@example.com, firstname.lastname@example.org or visit www.arcexperts.com.
News Article | November 1, 2016
Disruptive Software Startup Guides Researchers in Selecting Life Science Products for Experimentation with Objective, Peer-Reviewed Rating System -- an Industry-First PALO ALTO, CA--(Marketwired - Nov 1, 2016) - Bioz, Inc., developers of the world's first search engine for life science experimentation, today announced the release of its latest Bioz Stars technology. Bioz Stars is a fully objective product rating system that accelerates scientific discovery. "Researchers have been asking for an easier eCommerce purchasing process for laboratory products that would provide simple, evidence-supported comparison between competing brands and products," stated Frost & Sullivan Senior Life Science Industry Analyst Christi Bird. "The Bioz Stars platform fills that void, serving as an ideal starting place for laboratories to research products." Bioz' proprietary, multi-parameter algorithmic rating system is based on over a billion data points that have been extracted from tens of millions of peer-reviewed scientific articles using advanced Natural Language Processing (NLP) and Machine Learning (ML) technologies. The algorithm's parameters are weighted and normalized. The new Bioz Stars technology further enhances the industry's first and only unbiased rating system that is already in use by scientists around the world to help them quickly identify the best reagents, instruments, equipment and consumables for their experiments. The Bioz platform incorporates Bioz Star ratings to help guide researchers towards making the best, most well informed and transparent decisions possible, ensuring that their future experiments are better, quicker and more cost-effective. "The volume of reagents, consumables, equipment and instruments available for purchase is daunting," said Dr. Shai Saroussi, postdoctoral researcher at the Carnegie Institution at Stanford University. "With so many product options on the market from countless vendors, choosing the product that will work best in an experiment is painstaking. Once I started using the Bioz search engine, my research was transformed. Moreover, the integrated Bioz Stars product ratings are unbiased and based on millions of previously published peer-reviewed life science articles, allowing me to quickly and efficiently identify the best products for my experiments, helping me to conduct better, faster and more cost-effective research." Life science researchers in academia and biopharma spend $80 billion annually to purchase millions of products for their experiments -- from reagents to consumables to instruments and equipment. Many products, antibodies being a key example, have extremely high failure rates, leading to research delays and stalled drug discovery. Prior to Bioz Stars, there was not an easy way for researchers to either anticipate poorly performing and incompatible products, or to compare and select the best products to use in their specific assays and experiments. The new Bioz Stars technology release, available to users today, incorporates both new and enhanced rating parameters, including, but not limited to, the following: "The new features incorporated into our game-changing Bioz Stars rating system allow for unprecedented insights for life science researchers around the world who are planning their experiments," said Dr. Karin Lachmi, co-founder and chief scientific officer of Bioz. "At Bioz, we are continually looking for ways to improve the quality of scientific experimentation and ultimately speed up drug discovery and finding cures for diseases. Technology such as this, that helps scientists compare products for experimentation, was sorely lacking during my time as a researcher at Stanford University. We strive to have the Bioz Stars ratings technology align itself as closely as possible with how researchers actually think when deciding which products to use in their experiments." The Bioz platform and Bioz Stars are available free to researchers and scientists. Visit www.bioz.com, and start using Bioz today to find the best products for your experiments. Suggested Tweet: .@BiozPage announces the new Bioz Stars, the world's first unbiased algorithmic rating system for life science products http://bit.ly/2f6LAeF About Bioz, Inc. Bioz, Inc. offers the world's first search engine for life science experimentation. The patent-pending software platform combines the work of scientists with advanced Natural Language Processing (NLP) and Machine Learning (ML) to help life scientists in academia and biopharma make faster and smarter experimentation decisions, ultimately speeding up drug discovery and increasing the rate of success in finding cures for diseases. Founded in 2013 by Stanford research scientist, Karin Lachmi, Ph.D., and CEO Daniel Levitt, Bioz is a StartX accelerator company. Bioz is used by 60,000 researchers from over 5,000 universities and companies in 175 countries. Try Bioz at www.bioz.com.
News Article | November 14, 2016
BOCA RATON, FL--(Marketwired - November 14, 2016) - Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) announced today that Nathan Cali, formerly Noble's specialty pharmaceuticals senior analyst, has moved to its investment banking department. The move was timed to coincide with Noble's Investor Conference -- NobleCon13 to be held at the Boca Raton Resort & Club, January 30-31, 2017. Life science companies represent a significant portion of the presenting company roster at the conference. The sector is so important to Noble that it moved the date of the 2017 NobleCon back by two weeks in order to avoid a conflict with the JP Morgan Healthcare Conference set for early January in San Francisco. Mr Cali joined Noble in 2008 after gaining experience at Andrx Pharmaceuticals and Franklin Templeton. "As a senior analyst at Noble, Nathan has exhibited a "nose" for finding compelling investment ideas and themes for investors," said Noble's CEO Nico P. Pronk. A good example is a company that was recently acquired -- Cynapsus Therapeutics, Inc. for $624 million USD. In 2013, when the company's market capitalization was only $13.9 million, Noble was the first to initiate equity research coverage. Since that time, Cali has published 30 Cynapsus research reports and the company has attended two NobleCon Conferences. Noble has also supported the company's growth in investor awareness through three rounds of financing totaling in excess of $100 million USD, and through numerous non-deal road shows targeting fundamental science-driven institutional investors. Cynapsus is not the only company that has shown substantial growth. For example, Cali initiated coverage of TherapeuticsMD in 2013 when its market capitalization was $200 million, today it hovers around $1.0 billion; Axogen has grown from $28 million since initiation of research coverage in 2012 to over $280 million today. Cali also was early in identifying opportunities in the Hepatitis C space; Pharmasset's market cap was $173 million when he initiated -- the company was purchased a few years later by Gilead for $11 billion, and; Inhibitex was acquired by Bristol Myers Squibb for $2.5 billion and had a market capitalization in 2009 of $13 million when Noble initiated coverage. Cali was also instrumental in the creation (co-founder) of Variant Pharmaceuticals; a private early-stage life sciences company that will be entering into Phase 1 studies on the path to the commercialization of products designed to treat rare progressive forms of kidney disease. Noble believes that Mr. Cali's strong analytical healthcare background will provide great value to corporations in need of financing and strategic advice, and will further enhance our investment banking capabilities in the Noble Life Science Partners division. About Noble Financial Capital Markets Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton (HQ), New York and Boston. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences such as the Media, Finance & Investor Conference offered in partnership with the National Association of Broadcasters (NAB).
News Article | March 1, 2017
Receive press releases from IQ4I Research & Consultancy Pvt. Ltd.: By Email IQ4I Research & Consultancy Published a New Report on "Life Science Instruments and Reagents Global Market Forecast to 2023" The report covers all life instruments and associated reagents used in pharmaceuticals, biotechnology and diagnostics that help cutting edge research and innovative application. These technologies include from basic to advanced technologies, this report does not include medical devices or in-vitro diagnostics market; however the usage of instruments and reagents for diagnostic purpose is included in the market. Boston, MA, March 01, 2017 --( According to IQ4I analysis, the Life science instruments and reagents global market is expected to grow at high single digit to reach $81,325 million by 2023. The major factors driving the lifescience instruments and reagents market include increased focus on R&D expenditure and growth of biotechnology and pharmaceutical industries, technological advancements in analytical devices, growth in funding for research, rising demand of analytical instruments with growing research activities in proteomics, lucrative growth opportunities in emerging markets and increasing demand from various industries. Factors such as high cost of instruments, dearth of skilled professionals and stringent regulations are hampering the market growth. The report covers all life instruments and associated reagents used in pharmaceuticals, biotechnology and diagnostics that help cutting edge research and innovative application. These technologies include from basic to advanced technologies including spectrometry, chromatography, microscopy, PCR, flow cytometry, laboratory centrifuges, electrophoresis, NGS, biochips, automated liquid handling and robotics, cell counters, laboratory freezers and others. Among the technologies, spectrometry held the highest share and expected to grow at a mid single digit by 2023 due to their applications across all the disciplines of life science industry. Among the technologies, NGS is the fastest growing segment with mid double digit growth rate. Life science instruments and reagents global market by end users, pharmaceutical and biotechnology companies held the largest share and expected to grow at high single digit by 2023. Increasing demand for accurate and precise data for drug discovery and development has increased demand for spectrometry, chromatography, microscopy, PCR, flow cytometry, NGS and other life science instruments. Hospitals and diagnostic centers are fastest growing segment among end users with mid double digit growth rate. Some of the key players such as Agilent Technologies (U.S.), BD and Company (U.S.), Bio-Rad Laboratories (U.S.) Bruker Corporation (U.S.), Danaher Corporation (U.S.), Illumina, Inc. (U.S.), Merck KGaA (Germany), Perkinelemer, Inc. (U.S.), Roche Holdings (Switzerland), Shimadzu Corporation (Japan), Thermo Fisher Scientific, Inc. (U.S.) and Waters Corporation (U.S.). Some of the other players in the life science and instruments market include Qiagen N.V. (Netherlands), Abbott (U.S.), GE Healthcare (U.K.), Olympus (Japan), Nikon (Japan) , Tecan (Japan), Hitachi High-Tech (Japan), Biomeriex (France), Fluidigm (U.S.), Luminex (U.S.), Hamilton (U.S.), Pacific Biosciences (U.S.) Boston, MA, March 01, 2017 --( PR.com )-- Technological advancements in life science research across the globe has introduced a variety of techniques which are used by researchers for various applications including drug discovery and development, manufacturing, clinical diagnostics, basic research in genomic, proteomics, transcriptomics, metabolomics to cater the ever-growing needs of biotechnology and pharmaceutical, scientific equipments, life science research and services and diagnostics. Life Science instruments and reagents market comprises of technologies including Spectrometry, Chromatography, Microscopy, PCR, Flow Cytometry, Laboratory centrifuges, Electrophoresis, NGS, Biochips, Automated liquid handling and robotics, Cell Counters, Laboratory freezer and Others.According to IQ4I analysis, the Life science instruments and reagents global market is expected to grow at high single digit to reach $81,325 million by 2023. The major factors driving the lifescience instruments and reagents market include increased focus on R&D expenditure and growth of biotechnology and pharmaceutical industries, technological advancements in analytical devices, growth in funding for research, rising demand of analytical instruments with growing research activities in proteomics, lucrative growth opportunities in emerging markets and increasing demand from various industries. Factors such as high cost of instruments, dearth of skilled professionals and stringent regulations are hampering the market growth.The report covers all life instruments and associated reagents used in pharmaceuticals, biotechnology and diagnostics that help cutting edge research and innovative application. These technologies include from basic to advanced technologies including spectrometry, chromatography, microscopy, PCR, flow cytometry, laboratory centrifuges, electrophoresis, NGS, biochips, automated liquid handling and robotics, cell counters, laboratory freezers and others. Among the technologies, spectrometry held the highest share and expected to grow at a mid single digit by 2023 due to their applications across all the disciplines of life science industry. Among the technologies, NGS is the fastest growing segment with mid double digit growth rate.Life science instruments and reagents global market by end users, pharmaceutical and biotechnology companies held the largest share and expected to grow at high single digit by 2023. Increasing demand for accurate and precise data for drug discovery and development has increased demand for spectrometry, chromatography, microscopy, PCR, flow cytometry, NGS and other life science instruments. Hospitals and diagnostic centers are fastest growing segment among end users with mid double digit growth rate.Some of the key players such as Agilent Technologies (U.S.), BD and Company (U.S.), Bio-Rad Laboratories (U.S.) Bruker Corporation (U.S.), Danaher Corporation (U.S.), Illumina, Inc. (U.S.), Merck KGaA (Germany), Perkinelemer, Inc. (U.S.), Roche Holdings (Switzerland), Shimadzu Corporation (Japan), Thermo Fisher Scientific, Inc. (U.S.) and Waters Corporation (U.S.).Some of the other players in the life science and instruments market include Qiagen N.V. (Netherlands), Abbott (U.S.), GE Healthcare (U.K.), Olympus (Japan), Nikon (Japan) , Tecan (Japan), Hitachi High-Tech (Japan), Biomeriex (France), Fluidigm (U.S.), Luminex (U.S.), Hamilton (U.S.), Pacific Biosciences (U.S.) Click here to view the list of recent Press Releases from IQ4I Research & Consultancy Pvt. Ltd.
News Article | November 1, 2016
IRVINE, Calif., Nov. 1, 2016 /PRNewswire/ -- THIRD QUARTER 2016 AND RECENT HIGHLIGHTS -- EPS and FFO per share were $0.32 and $0.65, respectively; FFO as adjusted was $0.72 per share -- Completed spin-off of Quality Care Properties, Inc. ("QCP") (NYSE...